Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.54 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.54 |
| ▸ | DUT | P33316 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.42 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24487861 | 1.00 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL991867 | 1.00 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL15294575 | 1.00 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL25402577 | 1.00 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL991866 | 1.00 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL8642265 | 0.95 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL23710676 | 0.95 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL31749425 | 0.92 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL27397340 | 0.92 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL26567075 | 0.90 | DUT (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023224108-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | 株式会社GF・Mille | 2023-11-23 | — | — | WO | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230183701-A1 | Modified Double-Stranded RNA Agents | BANK OF AMERICA, N.A. | 2023-06-15 | — | — | US | disclosed |
| WO-2023049218-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-30 | — | — | WO | disclosed |
| US-11597932-B2 | Chirally-enriched double-stranded RNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-11549109-B2 | Modified double-stranded RNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220389424-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2022-12-08 | — | — | US | disclosed |
| US-11401517-B2 | Modified double-stranded RNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| US-20220119439-A1 | 5'-Cyclo-Phosphonate Modified Nucleotides | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-04-21 | — | — | US | disclosed |
| WO-2021234459-A9 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2022-02-03 | — | — | WO | disclosed |
| EP-3812462-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210017519-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2021-01-21 | — | — | US | disclosed |
| WO-2019217397-A2 | COMPOSITIONS AND METHODS FOR IMPROVING STRAND BIASED | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-11-14 | — | — | WO | disclosed |
| US-20190241893-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2019-08-08 | — | — | US | disclosed |
| US-20190241891-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2019-08-08 | — | — | US | disclosed |
| US-20190085012-A1 | 5'-Cyclo-Phosphonate Modified Nucleotides | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-03-21 | — | — | US | disclosed |
| US-10233448-B2 | Modified double-stranded RNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| WO-2017214112-A1 | 5'-CYCLO-PHOSPHONATE MODIFIED NUCLEOTIDES | Arrowhead Pharmaceuticals, Inc. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170275626-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2017-09-28 | — | — | US | disclosed |
| WO-2011005860-A2 | 5' PHOSPHATE MIMICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190085012-A1 | 5'-Cyclo-Phosphonate Modified Nucleotides | ENPP1, DCTPP1, DCLRE1B | SLC28A1 1239/4885SLC28A2 1299/4885SLC29A1 503/4885 |
| US-20220119439-A1 | 5'-Cyclo-Phosphonate Modified Nucleotides | ENPP1, DCTPP1, DCLRE1B | SLC28A1 1239/4885SLC28A2 1299/4885SLC29A1 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.